Durect Corp
DRRX Real Time Price USDRecent trades of DRRX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by DRRX's directors and management
Government lobbying spending instances
-
$20,000 Feb 11, 2008 Issue: Defense
-
$40,000 Aug 07, 2007 Issue: Defense
-
$40,000 Feb 12, 2007 Issue: Defense
-
$40,000 Aug 08, 2006 Issue: Defense
-
$40,000 Feb 14, 2006 Issue: Defense
Estimated quarterly lobbying spending
DRRX Revenue by Segment or Geography
New patents grants
-
Patent Title: Sustained release drug delivery systems with reduced impurities and related methods Oct. 03, 2023
-
Patent Title: Uses of oxygenated cholesterol sulfates (ocs) Mar. 28, 2023
-
Patent Title: Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same Dec. 20, 2022
-
Patent Title: Sustained release drug delivery systems with reduced impurities and related methods Aug. 02, 2022
-
Patent Title: Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material Mar. 29, 2022
-
Patent Title: Short duration depot formulations Nov. 23, 2021
-
Patent Title: Peroxide removal from drug delivery vehicle Aug. 10, 2021
-
Patent Title: Uses of oxygenated cholesterol sulfates (ocs) Sep. 29, 2020
-
Patent Title: Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same Sep. 01, 2020
-
Patent Title: Depot formulations Jun. 16, 2020
-
Patent Title: Depot formulations Jun. 02, 2020
-
Patent Title: Short duration depot formulations Nov. 12, 2019
-
Patent Title: Short duration depot formulations Nov. 12, 2019
-
Patent Title: Oral pharmaceutical dosage forms Jun. 25, 2019
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability May. 28, 2019
-
Patent Title: Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material Mar. 12, 2019
-
Patent Title: Oral pharamaceutical dosage forms Feb. 19, 2019
-
Patent Title: Short duration depot formulations Feb. 12, 2019
-
Patent Title: Depot formulations Jul. 24, 2018
-
Patent Title: Oral drug delivery system Mar. 20, 2018
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Mar. 06, 2018
-
Patent Title: Oral pharmaceutical dosage forms Feb. 06, 2018
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Jan. 02, 2018
-
Patent Title: Injectable controlled release composition comprising high viscosity liquid carrier Aug. 22, 2017
-
Patent Title: Oral pharmaceutical dosage forms May. 23, 2017
-
Patent Title: Oral pharmaceutical dosage forms Apr. 11, 2017
-
Patent Title: Sustained release small molecule drug formulation Mar. 21, 2017
-
Patent Title: Oral pharmaceutical dosage forms Mar. 14, 2017
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Feb. 21, 2017
-
Patent Title: Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material Feb. 21, 2017
-
Patent Title: Compositions with a rheological modifier to reduce dissolution variability Jan. 31, 2017
-
Patent Title: Oral drug delivery system Dec. 13, 2016
-
Patent Title: Oral drug delivery system Jan. 12, 2016
-
Patent Title: Sustained release small molecule drug formulation Jun. 02, 2015
-
Patent Title: Oral drug delivery system Mar. 10, 2015
-
Patent Title: Transdermal delivery systems Feb. 17, 2015
-
Patent Title: Oral drug delivery system Feb. 10, 2015
-
Patent Title: Oral drug delivery system Feb. 03, 2015
-
Patent Title: Zero-order prolonged release coaxial implants Nov. 18, 2014
-
Patent Title: Sustained release small molecule drug formulation Oct. 07, 2014
-
Patent Title: Controlled delivery system Sep. 30, 2014
-
Patent Title: Injectable, non-aqueous suspension with high concentration of therapeutic agent Aug. 12, 2014
-
Patent Title: Controlled delivery system Jun. 17, 2014
-
Patent Title: Transdermal analgesic systems with reduced abuse potential Jun. 10, 2014
-
Patent Title: Polymeric device for controlled release of active agents May. 13, 2014
-
Patent Title: Polymeric devices for controlled release of active agents Feb. 11, 2014
-
Patent Title: Non-aqueous single phase vehicles and formulations utilizing such vehicles Jul. 30, 2013
-
Patent Title: Transdermal analgesic systems with reduced abuse potential May. 14, 2013
-
Patent Title: Oral drug delivery system Apr. 16, 2013
-
Patent Title: Oral pharmaceutical dosage forms Apr. 09, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to DRRX
Recent picks made for DRRX stock on CNBC
ETFs with the largest estimated holdings in DRRX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $DRRX stock a Buy, Sell, or Hold?
- What is the price target for $DRRX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $DRRX stock?
- Who owns the most shares of $DRRX stock?
- What funds own $DRRX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DRRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.